Randomized Placebo-Controlled Trial of Tolvaptan in Hyponatremic Patients With Cancer
18 Years
N/A
Both
Advanced Cancers
Trial Information
Randomized Placebo-Controlled Trial of Tolvaptan in Hyponatremic Patients With Cancer
The Study Drug:
Tolvaptan is designed to help raise salt levels in your blood by removing extra body water
as urine.
Study Groups:
If you are found to be eligible to take part in this study, you will be randomly assigned
(as in the flip of a coin) to 1 of 2 groups. You will have an equal chance of being
assigned to either group:
- If you are in Group 1, you will take tolvaptan and receive standard of care
- If you are in Group 2, you will take a placebo and receive the standard of care for
patients with hyponatremia. A placebo is a tablet that looks like the study drug but
has no active ingredients.
You will not know which group you are assigned. However, if needed for your safety, you
will be able to find out what you are receiving at any time.
Study Drug Administration:
You will take tolvaptan or the placebo 1 time every day by mouth for 14 days.
If you are receiving the placebo, you will also receive the standard of care for
hyponatremia. Examples of the standard of care include limiting your water and fluid
intake, or giving you salt tablets and other drugs such as diuretics. Your doctor will
describe these in more detail.
You will be given a drug diary to record when you take the study drug/placebo. You will
return any unused drug/placebo at the end of 14 days.
You should avoid grapefruit and grapefruit juice while you are taking tolvaptan.
Study Visits:
At every visit, you will be asked if you have had any side effects.
On Days 1, 2, and 3:
- Blood (about 1 teaspoon) will be drawn for routine tests. On Day 1, this sample will be
drawn 2 times.
- Your weight and vital signs will be measured.
- The study staff will record how much fluid you are drinking and how much you are
urinating.
- You will be asked about any drugs that you may be taking.
- If the doctor thinks it is needed, you will have a physical exam.
On Day 7:
- Your medical history will be reviewed and updated.
- You will be asked about any drugs that you may be taking.
- Blood (about 1 teaspoon) will be drawn for routine tests and tests to measure how
concentrated your blood results are.
- Your weight and vital signs will be measured.
On Day 14:
- Your medical history will be reviewed and updated.
- Your weight and vital signs will be measured.
- Blood (about 1 teaspoon) and urine will be collected for routine tests and tests to
measure how concentrated your blood and urine are.
- The study staff will record how much fluid you are drinking and how much you are
urinating.
- You will be asked about any drugs that you may be taking.
- You will complete the MMSE.
If the doctor thinks it is needed, you will have a physical exam.
Length of Study:
You will take the study drug/placebo for 14 days. You will be taken off study if you have
intolerable side effects, if the disease gets worse, or if the study doctor thinks it is in
your best interest.
Your participation on the study will be over once you have completed the end-of-study visit.
End-of-Study- Day 30 Follow-up Visit:
At 30 days after the last dose of study drug (or placebo), you will have an end-of-study
visit in clinic or by telephone. At this visit, the following tests and procedures will be
performed.
- Your medical history will be reviewed and updated.
- Blood (about 1 teaspoon) will be drawn for routine tests and tests to measure how
concentrated your blood results are.
- You will be asked about any side effects that you may be having and any drugs that you
may be taking.
- The study staff will record how much fluid you are drinking and how much you are
urinating.
- If the doctor thinks it is needed, you will have a physical exam.
This is an investigational study. Tolvaptan is FDA approved and commercially available to
treat hyponatremia (low levels of salt [sodium] in the blood due to too much body water).
Its use in patients with cancer who have hyponatremia is investigational.
Up to 170 patients will take part in this study. All will be enrolled at MD Anderson.
Inclusion Criteria:
1. Euvolemic or hypervolemic (patients with heart or liver failure) with cancer admitted
to MD Anderson Cancer Center for any reasons with serum sodium between 125 and 130
mEq/L (both inclusive)
2. Patients must be greater than or equal to 18 years of age
3. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3 at
baseline.
4. Women of childbearing potential must use a medically accepted method of contraception
and to continue use of this method for the duration of the study and for 30 days
after study participation. Acceptable methods of contraception include abstinence,
barrier method with spermicide, intrauterine device (IUD), or steroidal contraceptive
(oral, transdermal, implanted, and injected) in conjunction with a barrier method.
Men must practice abstinence or use a barrier method of birth control, and must agree
to continue use for the duration of the study and for 30 days after study
participation.
5. Subjects must be able to comply with scheduled visits and follow-ups.
6. Informed consent must be signed
Exclusion Criteria:
1. History of hypersensitivity to tolvaptan
2. Patients admitted to the critical care unit.
3. Patients with renal failure(creatinine clearance less than 25 ml/min)
4. Patients with a life expectancy less than 3 months
5. Patients with volume depletion, BP < 100/60 or urinary sodium <20 meq/L.
6. Patients who are not able to swallow or cannot take medication through feeding tubes
7. Patients with diuretic-induced hyponatremia.
8. Patients with spurious hyponatremia
9. Patients with hyponatremia related to psychogenic polydypsia, head trauma, post
operative conditions, uncontrolled hypothyroidism or cortisol insufficiency or any
hyponatremia associated with the use of medication that can be safely withdrawn.
10. The use of alcohol while participating in the study
11. Currently taking demeclocycline, lithium, benzazepine derivatives, ketoconazole,
grapefruit, grapefruit juice and receiving strong CYP3A inhibitors such as
clarithromycin, fluconazole, voriconazole, posaconazole, itraconazole, ritonavir,
indinavir, nelfinavir, saquinavir, nefazodone, and telithromycin.
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Outcome Measure:
Proportion of Patients whose Serum Sodium Concentration Corrected to at least 135 mEq/L on Day 14
Outcome Description:
Compare proportion of hyponatremia cancer patients with a normalized serum sodium concentration at day 14 between those treated with Tolvaptan and those treated with a placebo (standard of care).
Outcome Time Frame:
14 days
Safety Issue:
Yes
Principal Investigator
Abdulla K. Salahudeen, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
UT MD Anderson Cancer Center
Authority:
United States: Food and Drug Administration
Study ID:
2009-0862
NCT ID:
NCT01199198
Start Date:
May 2011
Completion Date:
Related Keywords:
- Advanced Cancers
- Hyponatremia
- Serum sodium
- Tolvaptan
- Placebo
- Neoplasms
Name | Location |
|---|---|
| UT MD Anderson Cancer Center | Houston, Texas 77030 |
